OpenLobby.EU
Explore

Ogival

Conseil aux acteurs économiques pour les affaires européennes et autres conseils de gestion non réglementés; Rédaction de contenu sur tous types de supports; Apport d'affaires et formation non réglementée dans les domaines précités.

Lobbying Activity

Response to Biotech Act

11 Jun 2025

ErVimmune - Reflections on the financing of innovative European biotechnology companies Despite the existence of numerous public support schemes, innovative biotechnology companies without clinical data (yet)particularly in oncologystill struggle to secure the private funding necessary for their development in Europe. Their high-risk profile, combined with a lack of short-term revenues, leads to low interest from private investors even when public funding is associated (both dilutive and non-dilutive). Europes competitiveness in this strategic segment (i.e., innovative oncology therapies) is therefore hindered, especially in comparison to very dynamic North American and Asian ecosystems. In this regard, a note published on April 24, 2025, in Nature, the leading scientific journal, highlights Chinas rise, now ahead of the United States in the race to develop new oncology therapiesparticularly in terms of patents filed and clinical trials conducted; In this context, and based on the difficulties encountered during its Series A fundraising, ErVimmunea European biotech company without clinical data (ye) but a Beneficiary of the European Innovation Council (EIC) would like to share the following reflections and associated proposals enclosed.
Read full response